Erlangen, Germany

Nadja Spindler

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignee: 4-Antibody Ag. Active years: 2016.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Nadja Spindler. Retrieved from https://idiyas.com/inventor/nadja-spindler-y6a6vtxo

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile


 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 1(Granted Patents)


Company Filing History:


Years Active: 2016

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Nadja Spindler: Innovator in Human Cytomegalovirus Research

Introduction

Nadja Spindler is a prominent inventor based in Erlangen, Germany. She has made significant contributions to the field of virology, particularly in the study of human cytomegalovirus (hCMV). Her innovative work focuses on developing binding members that can neutralize the biological effects of hCMV.

Latest Patents

Nadja holds 1 patent for her invention titled "Binding members for human cytomegalovirus." This invention relates to antibody molecules that may be utilized for the treatment and prophylaxis of hCMV infection. The binding members she developed are crucial for advancing therapeutic options against this virus.

Career Highlights

Nadja Spindler is associated with 4-Antibody AG, a company dedicated to developing antibody-based therapies. Her work at the company has positioned her as a key figure in the fight against viral infections, particularly those caused by hCMV.

Collaborations

Throughout her career, Nadja has collaborated with notable colleagues, including Ulf Grawunder and Michael Mach. These partnerships have enhanced her research and contributed to the advancement of her innovative projects.

Conclusion

Nadja Spindler's contributions to the field of virology, particularly through her patent on binding members for hCMV, highlight her role as an influential inventor. Her work continues to pave the way for new therapeutic strategies against viral infections.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…